Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5424-5431

  Kusari, Jyotirmoy ^a   Padillo, Edwin ^a   Zhou, Sheila X ^a   Bai, Yanyan ^b,c   Wang, Juanjuan ^b,c   Song, Zhiming ^b,c   Zhu, Meili ^b,c   Le, Yun Zheng ^b,c   Gil, Daniel W ^a  

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; VASCULOTROPIN; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FIBROBLAST GROWTH FACTOR 2; OXYGEN; QUINOXALINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; IMMUNOBLOTTING; LOW LEVEL LASER THERAPY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; RETINA ANGIOGRAPHY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA NEOVASCULARIZATION; RETINOPATHY; RETROLENTAL FIBROPLASIA; SUBRETINAL NEOVASCULARIZATION; ANIMAL; BROWN NORWAY RAT; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LASER COAGULATION; PATHOLOGY; TIME;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTOR 2; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMMUNOBLOTTING; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; LASER COAGULATION; MALE; MICE; MICE, INBRED C57BL; OXYGEN; QUINOXALINES; RABBITS; RATS; RATS, INBRED BN; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; TIME FACTORS;

EID: 80052518059     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6262     Document Type: Article

References (41)

1. Campochiaro PA. Retinal and choroidal neovascularization. J Cell Physiol. 2000;184(3):301-310.
2. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM. Retinopathy of prematurity: recent advances in our understanding. Arch Dis Child Fetal Neonatal Educ. 2002;87(2):F78-F82.
3. Kowluru RA, Chan P-S. Capillary dropout in diabetic retinopathy. In: Duh E, ed. Diabetic Retinopathy: Contemporary Diabetes. Totowa, NJ: Humana Press; 2009:265-282.
4. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1):101-111.
5. Grunwald JE, Hariprasad SM, DuPont J, et al. Foveolar choroidal blood flow in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1998;39(2):385-390.
6. Adamis AP. The rationale for drug combinations in age-related macular degeneration. Retina. 2009;29(suppl):S42-S44.
7. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-985.
8. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843-845.
9. Murata T, Nakagawa K, Khalil A, Ishibashi T, Inomata H, Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74(4):819-825.
10. Stergiou PK, Symeonidis C, Dimitrakos SA. Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization. Acta Ophthalmol. 2011;89(3):218-221.
11. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156(2):697-707.
12. Xia XB, Xiong SQ, Song WT, Luo J, Wang YK, Zhou RR. Inhibition of retinal neovascularization by siRNA targeting VEGF(165). Mol Vis. 2008;14:1965-1973.
13. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A. 1996;93(10):4851-4856.
14. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92(3):905-909.
15. Bai Y, Ma JX, Guo J, et al. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. J Pathol. 2009;219(4): 446-454.
16. Wang J, Xu X, Elliott MH, Zhu M, Le YZ. Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes. 2010;59(9):2297-2305.
17. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996; 37(9):1929-1934.
18. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised agerelated macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):855-868.
19. Bressler SB. Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116(10 suppl):S1-S7.
20. Yi X, Ogata N, Komada M, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol. 1997;235(5):313-319.
21. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(10):3158-3164.
22. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol. 1999; 9(suppl 1):S17-S21.
23. 2-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296(1):216-223.
24. Mayor-Torroglosa S, De la Villa P, Rodríguez ME, et al. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005;46(10):3825-3835.
25. 2-selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2001;42(9): 2074-2084.
26. Vidal-Sanz M, Lafuente MP, Mayor-Torroglosa S, Aguilera ME, Miralles de Imperial J, Villegas-Pérez MP. Brimonidine's neuroprotective effects against transient ischaemia-induced retinal ganglion cell death. Eur J Ophthalmol. 2001;11(suppl 2):S36-S40.
27. Danylkova NO, Alcala SR, Pomeranz HD, McLoon LK. Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. Exp Eye Res. 2007;84(2):293-301.
28. Aktaş Z, Gürelik G, Akyürek N, Onol M, Hasanreisoǧlu B. Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model. Clin Exp Ophthalmol. 2007;35(6):527-534.
29. Kusari J, Zhou SX, Padillo E, Clarke KG, Gil DW. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest Ophthalmol Vis Sci. 2010;51(2):1044-1051.
30. Campos M, Amaral J, Becerra SP, Fariss RN. A novel imaging technique for experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006;47(12):5163-5170.
31. Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci. 2007; 48(11):5152-5159.
32. Ni M, Holland M, Jarstadmarken H, De Vries G. Time-course of experimental choroidal neovascularization in Dutch-Belted rabbit: clinical and histological evaluation. Exp Eye Res. 2005;81(3):286-297.
33. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008; 118(2):526-533.
34. Lange C, Ehlken C, Stahl A, Martin G, Hansen L, Agostini HT. Kinetics of retinal vaso-obliteration and neovascularisation in the oxygen-induced retinopathy (OIR) mouse model. Graefes Arch Clin Exp Ophthalmol. 2009;247(9):1205-1211.
35. Ni J, Yuan X, Gu J, et al. Clinical Genomic and Proteomic AMD Study Group. Plasma protein pentosidine and carboxymethyllysine, biomarkers for age-related macular degeneration. Mol Cell Proteomics. 2009;8(8):1921-1933.
36. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999;5:32.
37. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003;52(3):864-871.
38. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271(2):736-741.
39. Yang XM, Wang YS, Zhang J, et al. Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization. Invest Ophthalmol Vis Sci. 2009;50(4):1873-1879.
40. Wheeler L, Woldemussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48(suppl 1):S47-S51.
41. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008;49(10):4515-4522.